NOVAVAX INC (NVAX)       21.33  +2.46 (+13.04%)

7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’

Investors have seven widely-followed vaccine stocks to sell now, after the world decided the pandemic is over.

MarketBeat: Week in Review 9/19 – 9/23

The sell-off in the market confirms that the global economy is slowing. What should you do? Here are some insights our analysts delivered for you this week

Noteworthy Thursday Option Activity: BYND, PYPL, NVAX

Here Are Novavax's U.S. Vaccination Numbers — And They're Bleak

In the U.S., Novavax is going after the 10% of unvaccinated adults.

What Is Going on With Accenture (ACN) Stock Today?

Accenture (ACN) stock is on the move Thursday after releasing a positive earnings report and announcing a new acquisition.

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement

Spero Therapeutics (SPRO) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (GSK).

Why Is Novavax (NVAX) Stock Falling Today?

Novavax still has cash, but it needs to get approval for another vaccine if NVAX stock is to be worth buying again.

Novavax Remains a Risk-On Stock in a Risk-Off Market

NVAX is a risk-on stock at a time investors are turning to risk-off assets. This article looks to see if Novavax still presents an opportunity for investors

Why Are Vaccine Stocks MRNA, PFE, NVAX, BNTX Down Today?

Vaccine stocks are taking it on the chin following President Joe Biden's comments that the "pandemic is over." What now?

Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...

Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...

Le vaccin Nuvaxovid™ de Novavax contre la COVID-19 obtient une autorisation de mise sur le marché conditionnelle étendue dans l'Union européenne pour son utilisation en tant que rappel chez les adultes âgés de 18 ans et plus

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), société de biotechnologie spécialisée dans le développement et la commercialisation de vaccins de nouvelle...

Novavax Nuvaxovid™ Covid-19-Impfstoff erhält erweiterte bedingte Marktzulassung in der Europäischen Union zur Verwendung als Auffrischungsimpfung für Erwachsene ab 18 Jahren

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten...

Notable Tuesday Option Activity: BLK, ETSY, NVAX

La vacuna Novavax Nuvaxovid™ COVID-19 recibe autorización de comercialización condicional ampliada en la UE

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y comercializar vacunas de nueva generación contra...

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...

NVAX October 28th Options Begin Trading

Novavax to Participate in Upcoming September Conferences

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...